Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.34) by...

https://nypost.com/2024/06/27/lifestyle/weight-loss-drug-pemvidutide-may-be-better-than-ozempic-trial/

Altimmune shares are experiencing significant movement lower following the unexpected passing of Richard Eisenstadt, the compan...

B. Riley Securities analyst Mayank Mamtani reiterates Altimmune (NASDAQ:ALT) with a Buy and maintains $20 price target.

Altimmune said it presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide, including the results of a re...

ALNY: 14% | Alnylam Pharmaceuticals shares are trading higher after the company announced topline results from its HELIOS-B Pha...

Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today presented data from the 48-week Phase 2 MOMENTU...